There’s much more to the deal than just a $3b takeover offer; Merck stood to gain through milestones and royalties anyway.
I’m unsure of the details but see below:
Under the terms of the license agreement, Merck KGaA will receive an upfront payment as well as a minority equity stake in MoonLake Immunotherapeutics. Merck KGaA is eligible for potential development and commercial milestone payments as well as industry-standard royalties on net sales.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.85 |
Change
0.220(1.32%) |
Mkt cap ! $2.095B | |||
| Open | High | Low | Value | Volume |
| $16.80 | $16.89 | $16.63 | $788.0K | 47.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27 | $16.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.86 | 59 | 2 |
View Market Depth
| Last trade - 10.34am 31/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |